Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia.

Jereb M, Kotar T.

Wien Klin Wochenschr. 2006 Apr;118(5-6):170-4.

PMID:
16773483
2.

Procalcitonin is useful in identifying bacteraemia among children with pneumonia.

Nascimento-Carvalho CM, Cardoso MR, Barral A, Araújo-Neto CA, Guerin S, Saukkoriipi A, Paldanius M, Vainionpää R, Lebon P, Leinonen M, Ruuskanen O, Gendrel D.

Scand J Infect Dis. 2010 Sep;42(9):644-9. doi: 10.3109/00365541003796775.

PMID:
20438288
3.

Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD.

Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR, Nicholson KG, Brightling CE.

Chest. 2011 Jun;139(6):1410-1418. doi: 10.1378/chest.10-1747. Epub 2010 Oct 28.

4.
5.

Procalcitonin in children admitted to hospital with community acquired pneumonia.

Moulin F, Raymond J, Lorrot M, Marc E, Coste J, Iniguez JL, Kalifa G, Bohuon C, Gendrel D.

Arch Dis Child. 2001 Apr;84(4):332-6.

6.

Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.

Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B.

Am J Respir Crit Care Med. 2006 Jul 1;174(1):84-93. Epub 2006 Apr 7.

PMID:
16603606
7.

Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.

Ugajin M, Yamaki K, Hirasawa N, Yagi T.

Respir Care. 2014 Apr;59(4):564-73. doi: 10.4187/respcare.02807. Epub 2013 Oct 29.

8.

The utility of biomarkers in differentiating bacterial from non-bacterial lower respiratory tract infection in hospitalized children: difference of the diagnostic performance between acute pneumonia and bronchitis.

Hoshina T, Nanishi E, Kanno S, Nishio H, Kusuhara K, Hara T.

J Infect Chemother. 2014 Oct;20(10):616-20. doi: 10.1016/j.jiac.2014.06.003. Epub 2014 Jul 11.

PMID:
25027057
9.

Empiric antimicrobial therapy of community-acquired pneumonia: clinical diagnosis versus procalcitonin levels.

Cunha BA.

Scand J Infect Dis. 2009;41(10):782-4. doi: 10.1080/00365540903147035. No abstract available.

PMID:
19681019
10.

Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia.

Kang YA, Kwon SY, Yoon HI, Lee JH, Lee CT.

Korean J Intern Med. 2009 Dec;24(4):337-42. doi: 10.3904/kjim.2009.24.4.337. Epub 2009 Nov 27.

11.

Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children.

Toikka P, Irjala K, Juvén T, Virkki R, Mertsola J, Leinonen M, Ruuskanen O.

Pediatr Infect Dis J. 2000 Jul;19(7):598-602.

PMID:
10917215
12.

Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index.

Masiá M, Gutiérrez F, Shum C, Padilla S, Navarro JC, Flores E, Hernández I.

Chest. 2005 Oct;128(4):2223-9.

PMID:
16236878
13.

C-reactive protein, procalcitonin, clinical pulmonary infection score, and pneumonia severity scores in nursing home acquired pneumonia.

Porfyridis I, Georgiadis G, Vogazianos P, Mitis G, Georgiou A.

Respir Care. 2014 Apr;59(4):574-81. doi: 10.4187/respcare.02741. Epub 2013 Oct 8.

14.

Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia.

Zhydkov A, Christ-Crain M, Thomann R, Hoess C, Henzen C, Werner Z, Mueller B, Schuetz P; ProHOSP Study Group.

Clin Chem Lab Med. 2015 Mar;53(4):559-66.

PMID:
25014522
15.

Procalcitonin: inflammatory biomarker for assessing the severity of community-acquired pneumonia--a clinical observation in geriatric patients.

Heppner HJ, Bertsch T, Alber B, Esslinger AS, Dragonas C, Bauer JM, Sieber CC.

Gerontology. 2010;56(4):385-9. doi: 10.1159/000262285. Epub 2009 Nov 25.

PMID:
19940454
16.

Procalcitonin levels are lower in intensive care unit patients with H1N1 influenza A virus pneumonia than in those with community-acquired bacterial pneumonia. A pilot study.

Piacentini E, Sánchez B, Arauzo V, Calbo E, Cuchi E, Nava JM.

J Crit Care. 2011 Apr;26(2):201-5. doi: 10.1016/j.jcrc.2010.07.009. Epub 2010 Sep 1.

PMID:
20813489
17.

Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis.

Polzin A, Pletz M, Erbes R, Raffenberg M, Mauch H, Wagner S, Arndt G, Lode H.

Eur Respir J. 2003 Jun;21(6):939-43.

18.

The value of procalcitonin level in community-acquired pneumonia in the ED.

Park JH, Wee JH, Choi SP, Oh SH.

Am J Emerg Med. 2012 Sep;30(7):1248-54. doi: 10.1016/j.ajem.2011.08.009. Epub 2011 Oct 24.

PMID:
22030193
19.

Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note.

Falsey AR, Becker KL, Swinburne AJ, Nylen ES, Snider RH, Formica MA, Hennessey PA, Criddle MM, Peterson DR, Walsh EE.

Int J Chron Obstruct Pulmon Dis. 2012;7:127-35. doi: 10.2147/COPD.S29149. Epub 2012 Feb 23.

20.

Usefulness of serum procalcitonin levels in pulmonary tuberculosis.

Ugajin M, Miwa S, Shirai M, Ohba H, Eifuku T, Nakamura H, Suda T, Hayakawa H, Chida K.

Eur Respir J. 2011 Feb;37(2):371-5. doi: 10.1183/09031936.00011910. Epub 2010 Jun 7.

Supplemental Content

Support Center